CanSino Biologics Inc. (FRA:CJH)

Market Cap	1.54B
Revenue (ttm)	116.35M
Net Income (ttm)	-17.00M
Shares Out	n/a
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	53.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	83
Open	4.404
Previous Close	4.420
Day's Range	4.400 - 4.404
52-Week Range	3.120 - 6.000
Beta	n/a
RSI	37.09
Earnings Date	Mar 25, 2026

About CanSino Biologics

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 1,105
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CJH

Financial Performance

In 2024, CanSino Biologics's revenue was 846.34 million, an increase of 137.01% compared to the previous year's 357.08 million. Losses were -378.88 million, -74.45% less than in 2023.

Financial numbers in CNY